On 27 January 2026, India and the European Union concluded negotiations on a comprehensive free trade agreement (FTA) after nearly two decades of on-and-off talks, a deal already being called the “mother of all deals” in trade circles. The agreement is not yet in force. It still has to clear legal review, a Council decision to sign, a consent vote in the European Parliament, and approval by Indian authorities, a sequence that has taken other EU trade agreements anywhere from several months to several years to complete, depending on whether provisions like investment protection require ratification by individual member states. This deal is expected to clear that process and take effect by early 2027.
For European medical technology OEMs, medical devices are named explicitly as a benefiting sector. India has committed to eliminating or reducing tariffs on 86% of tariff lines and 93% of trade value, including industrial and medical duties that have historically averaged above 16% and, for some device categories, run as high as 30%. Beyond tariffs, the agreement introduces mechanisms for regulatory cooperation, transparency, customs facilitation, and a dedicated Working Group on Conformity Assessment tasked with aligning Indian and international standards. None of this changes what a device must do to enter the European market. It changes what it costs to get there.
That distinction is the decision this agreement forces on procurement. Companies can treat India as another marginal, cost-driven source, or as a qualified, compliant node inside a diversified global supply chain, a distinction Section 8 addresses in full. The agreement is concluded but not yet active, which is precisely why the period ahead is a planning window: companies that begin partner qualification and pilot work now will be positioned to scale the moment reduced duties take effect.
Negotiations on the India-EU Free Trade Agreement concluded on 27 January 2026, after nearly two decades of intermittent discussion that had been paused and restarted multiple times over tariffs, market access, professional mobility, intellectual property, and sustainability commitments. Conclusion is not the same as entry into force. Before the agreement takes effect, it must pass through legal and technical review and translation of the text, a Council decision authorizing signature, a consent vote in the European Parliament, and approval by Indian authorities. If elements such as investment protection are treated as part of a “mixed” agreement covering areas beyond trade, individual EU member state parliaments may also need to ratify those elements separately, a step that has taken comparable EU trade agreements several years to complete. This deal is expected to clear the process and enter into force by early 2027, roughly a year after conclusion, toward the faster end of that range but still leaving a real gap between agreed and active.
That gap is where medical technology OEMs should focus. India has committed to eliminating or reducing tariffs on 86% of tariff lines and 93% of trade value, with industrial goods duties, which have historically averaged above 16%, falling accordingly. Medical devices are named explicitly as a benefiting sector, with duties on medical goods moving from Europe into India historically running as high as 30% across categories including diagnostic equipment, imaging systems, in-vitro diagnostic products, patient monitoring devices, surgical instruments, orthopedic products, and high-value consumables and components.
To translate that into scale: EU exports of optical, photo, technical, and medical apparatus into India totaled $4.14 billion in 2025, the trade flow these tariff cuts apply against. Tariff-adjusted cost modeling, the same lens SJML uses elsewhere to weigh landed cost against a shifting duty structure, makes the effect concrete: on a representative $1 million shipment of European-made diagnostic or monitoring equipment, a 30% duty adds $300,000 in tariff cost, and as that duty phases toward zero, the same shipment’s landed cost falls by a corresponding amount. Extended across a multi-year sourcing commitment, such as a five-year supply agreement for a mid-volume consumable line, this differential compounds into a material shift in program economics, one substantial enough to influence whether India or a competing geography secures the allocation. The direction of travel matters as much as the size: in August 2025, the United States raised its tariff on Indian medical device imports from 26% to 50%, while the EU-India agreement moves the opposite way, toward zero duty on the large majority of tariff lines. For an OEM sourcing globally, that divergence changes the relative economics of an Indian manufacturing footprint depending on which market the finished device is headed to, a distinction procurement teams modeling landed cost should build into their assumptions rather than treating India as a single, uniform sourcing decision.
None of this alters what a device must do to reach the European market. An India-manufactured device intended for Europe must still satisfy every applicable requirement under EU MDR and IVDR in full: the same quality management system standards, technical documentation, clinical evidence, post-market surveillance, and conformity assessment obligations that apply today will apply after the agreement takes effect. A lower tariff is a commercial input. It is not a regulatory shortcut.
Discussions surrounding the India-Europe trade agreement have largely centered on the improved market access for European products in the Indian market. Nonetheless, a suitable implication of the deal for the procurement executive is to present India as a manufacturing base for broader medical goods and the distribution of medical technology.
Moving forward, it is, however, important to steer clear of the distinction between the structural advancements in regulatory cooperation and the tariff relief applied to finished medical goods. The former benefits exporters. The latter offers the groundwork for considering India as a long-term, qualified node for sub-assembly and component manufacturing. By eschewing transactional buying, business firms can build a more robust supply chain that incorporates top-notch manufacturing facilities into their global networks.
A greater transparency for sourcing decisions should emerge from the agreement’s provisions concerning international standards promotion and technical trade barriers. In order to standardize Indian quality control orders into compliance with globally accepted norms, a specialized Working Group on Conformity Assessment is being established.
To presume that full mutual recognition is in place at this time would be misleading. Instead of eliminating all regulatory barriers outright, the convergence outlined in the agreement is directional rather than immediate. For example, the Working Group on Conformity Assessment is tasked with aligning India’s Quality Control Orders with international standards such as ISO 13485 and IEC 60601, not with granting automatic recognition of EU conformity marks. For regulatory affairs and quality teams managing multiple jurisdictions, that distinction determines how much of their current compliance workload the agreement actually removes, and for now, the answer is very little.
Owing to the development of dedicated device parks and state incentives, India boasts a technologically advanced manufacturing ecosystem. MedTech parks in Andhra Pradesh (Visakhapatnam), Telangana (Hyderabad), Tamil Nadu (Chennai), and Himachal Pradesh (Baddi) broadly define the manufacturing landscape. As the hubs of the new India-Europe trade corridor, these zones supply the infrastructure required for an integrated “design-to-build” framework. It is primarily due to these initiatives that domestic manufacturing capacity is expected to witness more advancement and expansion.
With that said, an informed procurement executive will look beyond the superficial optimism as India remains heavily dependent on imports for essential raw materials. Additionally, its regulatory culture is also currently undergoing the requisite professionalization. The “audit readiness” gap is the most common barrier to overcome. Many domestic contract manufacturers find it difficult to keep up with the complex forensic documentation requirements of the EU MDR and local CDSCO regulations.
For enterprises looking to reduce the risks associated with concentrated supply chains and pursue a China-plus-one strategy, the agreement offers a timely advantage. It creates a politically backed corridor that enables European companies to add an Indian node to their existing manufacturing portfolio.
This is notably relevant when it comes to the production of categories such as:
Companies can thus increase resiliency without violating quality or legal requirements by reallocating these categories to certified partners.
Reduced tariffs by themselves do not prepare the supply chain. Manufacturing capacity determines the shift from reduced landed costs to medical products that are ready for the market. Therefore, procurement teams should assess potential partners based on a number of factors.
Traceability and post-market readiness: Creating a system that is capable of handling effective corrective and preventive actions (CAPA), and unit-level traceability. Also, promoting a transparent mechanism for ensuring cleaner audits.
Depending on the identified sourcing objectives, different operating models will be developed.
The strategic direction of the agreement has now been effectively established. Business firms that are geared up for implementation will reap the advantages from this agreement long before the new duties are applied. By initiating the pilot production and partner qualification process early on, companies will be in a much better position to scale up their operations as soon as the agreement comes into effect.
Simply put, the selection of an experienced manufacturing partner will largely decide whether companies can translate tariff advantages into scalable and economically viable business outcomes. Syrma Johari MedTech (SJML) operates as a design-led, MedTech-exclusive contract design and manufacturing organization (CDMO). From conception to commercialization, it offers comprehensive solutions covering the whole product lifecycle. Its facilities are designed to operate as qualified, compliant nodes that meet the strict audit requirements of QARA teams as well as board-level diversification mandates. SJML helps close the execution gap between reduced landed costs and market-ready compliance as a strategic partner to international MedTech innovators.
SJML follows a strong structural framework that includes precision plastics manufacturing, in-house PCBA, and ISO 7 and 8 cleanrooms. With a track record of serving more than 325 clients across more than 80 international markets, SJML supports 11 key technologies, including RF, ultrasound, and microfluidics. The MedTech CDMO’s manufacturing DNA incorporates a QARA framework, which guarantees smooth compliance with CDSCO, EU MDR/IVDR, and US FDA 510(k)/MDSAP standards. SJML partners have consistently achieved 30-40% faster time-to-market and significant cost savings by using our design-led manufacturing model.
For MedTech OEMs seeking to establish India as a qualified manufacturing and sourcing node, early engagement with experienced partners can offer a huge strategic advantage. Contact Syrma Johari MedTech to understand how our turnkey capabilities can accelerate your innovation and market readiness.
Q. Is the agreement in force yet, and when can we expect tariff changes?
No, the agreement is yet to come into effect. However, formal ratification is underway and is expected to lead to implementation in early 2027.
Q. Does the FTA remove the need for CE marking on India-made devices?
No, the agreement does not alter any regulatory requirements. The standards for quality management systems, technical documentation, clinical evidence, post-market surveillance, and conformity assessments will still remain unchanged.
Q. Which device categories benefit most from the tariff changes?
Medical device categories, particularly high-volume consumables, printed circuit board assemblies, and precision sub-assemblies, are more likely to experience immediate benefit. Some of them are: diagnostic consumables and cartridges, IVD readers and instrumentation, precision plastic components, PCBAs, disposable medical devices, and certain electromechanical sub-assemblies.
Q. How does India compare with Vietnam or Malaysia for MedTech sourcing?
The agreement will position India as a dependable, cost-driven secondary source, offering several structural advantages, such as a large engineering talent base, a rapidly expanding medical device ecosystem, government-backed manufacturing incentives, and growing domestic demand. However, more mature markets like Vietnam and Malaysia will continue to possess strengths in product categories and sourcing priorities.
Q. What is the realistic timeline to qualify an Indian CDMO?
The process timeline will be initiated to ensure that systems are compliant by the expected date of entry into force. However, supplier qualification, audits, process validation, transfer activities, and regulatory documentation can take several months to more than a year for highly regulated products.
Q. Does sourcing in India create IP or data-security exposure?
India presents both opportunities and risks. As is customary in global sourcing engagements, firms are advised to conduct thorough and rigorous due diligence on the contract framework and governance mechanisms before proceeding.
